Bristol-Myers' Mike Burgess Talks R&D Challenges, Portfolio Developments In 2017
Dr. Mike Burgess, the head of several disease R&D areas at Bristol-Myers Squibb, talks to Scrip on the side lines of the recent One Nucleus Genesis conference in London, UK, about the importance of a diverse portfolio, balancing R&D budgets and his industry-wide predictions for 2017.
You may also be interested in...
Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2021. Data provided by Biomedtracker.
For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.